Molecular profiling of platinum resistant ovarian cancer

The aim of this study is to discover a gene set that can predict resistance to platinum‐based chemotherapy in ovarian cancer. The study was performed on 96 primary ovarian adenocarcinoma specimens from 2 hospitals all treated with platinum‐based chemotherapy. In our search for genes, 24 specimens of the discovery set (5 nonresponders and 19 responders) were profiled in duplicate with 18K cDNA microarrays. Confirmation was done using quantitative RT‐PCR on 72 independent specimens (9 nonresponders and 63 responders). Sixty‐nine genes were differentially expressed between the nonresponders (n = 5) and the responders (n = 19) in the discovery phase. An algorithm was constructed to identify predictive genes in this discovery set. This resulted in 9 genes (FN1, TOP2A, LBR, ASS, COL3A1, STK6, SGPP1, ITGAE, PCNA), which were confirmed with qRT‐PCR. This gene set predicted platinum resistance in an independent validation set of 72 tumours with a sensitivity of 89% (95% CI: 0.68–1.09) and a specificity of 59% (95% CI: 0.47–0.71)(OR = 0.09, p = 0.026). Multivariable analysis including patient and tumour characteristics demonstrated that this set of 9 genes is independent for the prediction of resistance (p < 0.01). The findings of this study are the discovery of a gene signature that classifies the tumours, according to their response, and a 9‐gene set that determines resistance in an independent validation set that outperforms patient and tumour characteristics. A larger independent multicentre study should further confirm whether this 9‐gene set can identify the patients who will not respond to platinum‐based chemotherapy and could benefit from other therapies. © 2005 Wiley‐Liss, Inc.

[1]  A. Lavoinne,et al.  Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. , 2003, European journal of biochemistry.

[2]  Trevor Hastie,et al.  Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.

[3]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[4]  K. Aihara,et al.  Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analyses. , 1997, American journal of clinical pathology.

[5]  S. de Jong,et al.  Effect of novobiocin on cisplatin cytotoxicity and dna interstrand cross‐link formation in a cisplatin‐resistant, small‐cell lung carcinoma cell line , 1993, International journal of cancer.

[6]  M. Buyse,et al.  The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.

[7]  David I. Smith,et al.  Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy , 2005, Clinical Cancer Research.

[8]  Christopher Haslett,et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.

[9]  G Rennert,et al.  Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. , 2001, The American journal of pathology.

[10]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Venkitaraman,et al.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. , 2003, Cancer cell.

[12]  S. Abdulkadir,et al.  A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance , 2004, Oncogene.

[13]  Kaori Sasai,et al.  Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 , 2004, Nature Genetics.

[14]  S. Kaye,et al.  Ovarian cancer: progress and continuing controversies in management. , 2002, European journal of cancer.

[15]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[16]  F. Oesch,et al.  Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. , 1999, Cancer research.

[17]  F. Bray,et al.  Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.

[18]  Maurice P H M Jansen,et al.  Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Buyse,et al.  The Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer , 1996 .

[20]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[21]  M. Hagiwara,et al.  Regulation of Binding of Lamin B Receptor to Chromatin by SR Protein Kinase and cdc2 Kinase in Xenopus Egg Extracts* , 2004, Journal of Biological Chemistry.

[22]  Hiroshi Katayama,et al.  The Aurora kinases: Role in cell transformation and tumorigenesis , 2003, Cancer and Metastasis Reviews.

[23]  Joos Vandewalle,et al.  Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma , 2001, The Lancet.

[24]  Stephen S. Taylor,et al.  Aurora-kinase inhibitors as anticancer agents , 2004, Nature Reviews Cancer.

[25]  S. Love,et al.  Proliferating cell nuclear antigen (PCNA) immunostaining--a prognostic factor in ovarian cancer? , 1995, British Journal of Cancer.

[26]  Jacques Robert,et al.  Molecular Determinants of the Cytotoxicity of Platinum Compounds , 2004, Cancer Research.

[27]  Il-Jin Kim,et al.  Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays , 2004, Clinical Cancer Research.

[28]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[29]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[30]  J. Bomalaski,et al.  Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. , 2002, Cancer research.

[31]  D. M. Parkin,et al.  Corrigendum to “Cancer burden in the year 2000. The global picture” [European Journal of Cancer,37(Suppl. 8) (2001) S4–S66] , 2003 .

[32]  Chris Cheadle,et al.  Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. , 2002, Cancer research.

[33]  J. Barret,et al.  A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity. , 1994, Molecular pharmacology.

[34]  T. Yoshida,et al.  Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. , 1997, Leukemia research.

[35]  A. Harris,et al.  Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[36]  F. Izzo,et al.  Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Zhenfeng Duan,et al.  Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. , 2003, Cancer research.

[38]  Robert C. Bast,et al.  Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.

[39]  H. Inoue,et al.  Immunohistochemical study of glutathione‐related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity , 1993, Cancer.

[40]  M. Gore,et al.  Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. , 2002, The Lancet. Oncology.

[41]  J. Verweij,et al.  Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer , 2002, British Journal of Cancer.

[42]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[43]  T Tanaka,et al.  Identification by cDNA microarray of genes involved in ovarian carcinogenesis. , 2000, Cancer research.

[44]  L. Mariani,et al.  Gene expression of DNA topoisomerases I, IIα and IIβ and response to cisplatin‐based chemotherapy in advanced ovarian carcinoma , 1996 .

[45]  E. Wiemer,et al.  Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. , 2004, Neoplasia.

[46]  Roger E Bumgarner,et al.  Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. , 1999, Gene.

[47]  B. Teicher,et al.  DNA Topoisomerase II α Expression Is Associated with Alkylating Agent Resistance , 1995 .

[48]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[49]  A. W. Boersma,et al.  SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. , 2001, Cancer research.

[50]  W. Dalton,et al.  Mechanisms Associated with cell Adhesion Mediated Drug Resistance (CAM-DR) in Hematopoietic Malignancies , 2004, Cancer and Metastasis Reviews.

[51]  P B Laub,et al.  Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells , 2005, British Journal of Cancer.

[52]  K. Tsuchida,et al.  Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins , 2004, Pancreas.

[53]  G. Maga,et al.  Proliferating cell nuclear antigen (PCNA): a dancer with many partners , 2003, Journal of Cell Science.

[54]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[55]  K. Münstedt,et al.  Influence of surgery and postoperative therapy and tumor characteristics on patient prognosis in advanced ovarian carcinomas. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[56]  T. Walsh,et al.  Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. , 1994, Cancer.